Clofibrate
- CAS No.
- 637-07-0
- Chemical Name:
- Clofibrate
- Synonyms
- LIP1;CPIB;ELPI;EPIB;LIP.1;yoclo;Artes;Bresit;Liprin;Normat
- CBNumber:
- CB5774380
- Molecular Formula:
- C12H15ClO3
- Molecular Weight:
- 242.7
- MOL File:
- 637-07-0.mol
- Modify Date:
- 2023/6/30 15:45:59
| Melting point | <25 °C |
|---|---|
| Boiling point | 154 °C |
| Density | 1.14 g/mL at 25 °C(lit.) |
| refractive index |
n |
| Flash point | 113 °C |
| storage temp. | 2-8°C |
| solubility | Soluble to 100 mM in DMSO. |
| form | liquid |
| color | clear, colorless |
| Water Solubility | 97.08mg/L(room temperature) |
| Merck | 14,2377 |
| BRN | 1913459 |
| CAS DataBase Reference | 637-07-0(CAS DataBase Reference) |
| IARC | 3 (Vol. Sup 7, 66) 1996 |
| NIST Chemistry Reference | Clofibrate(637-07-0) |
| EPA Substance Registry System | Clofibrate (637-07-0) |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |   GHS05,GHS07 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H302-H315-H318-H335 | |||||||||
| Precautionary statements | P261-P264-P280-P301+P312-P302+P352-P305+P351+P338 | |||||||||
| Hazard Codes | Xn,N | |||||||||
| Risk Statements | 22-37/38-41-51/53-40 | |||||||||
| Safety Statements | 26-36/37/39-61-45-36/37 | |||||||||
| RIDADR | UN 3082 9/PG 3 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | UE9480000 | |||||||||
| HazardClass | 9 | |||||||||
| HS Code | 29189900 | |||||||||
| Toxicity | LD50 in mice, rats (g/kg): 1.28, 1.65 orally (Metz) | |||||||||
| NFPA 704 |
|
Clofibrate price More Price(7)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | C6643 | Clofibrate liquid | 637-07-0 | 250MG | ₹6538.3 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C6643 | Clofibrate liquid | 637-07-0 | 1G | ₹7014.6 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C6643 | Clofibrate liquid | 637-07-0 | 5G | ₹25536.18 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | C6643 | Clofibrate liquid | 637-07-0 | 10G | ₹45973.78 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | 41326 | Clofibrate analytical standard | 637-07-0 | 100MG | ₹6852.23 | 2022-06-14 | Buy |
Clofibrate Chemical Properties,Uses,Production
Description
Researchers in France observed in 1953 that structures derived
from dehydrocholic acid, phenylethyl acetic acid, and certain
other disubstituted acetic acids exhibited hypocholesterolemic
properties in rats and humans. Several years later, Thorp and
Waring discovered clof ibrate as an effective compound for
lowering lipids in animal models, with minimal toxicity. Its
mode of action was initially attributed to seasonal variations in
adrenal and thyroid function, and the administration of
androsterone was found to potentiate the hypocholesterolemic
effect of this compound. Subsequently, several clinical trials
were performed which showed that clofibrate decreases lipid
levels in hypercholesterolemic patients, mainly as the result of
a reduction in the very-low-density lipoprotein (VLDL), and
less in the low-density lipoprotein (LDL) fraction, and that the
coadministration of androsterone was not necessary for its
hypolipidemic effect. Despite reported hepatomegaly in rats
following long-term treatment with clofibrate, this drug was
approved in the United States in 1967 for the treatment of
hyperlipidemias.
Clofibrate can be chemically synthesized by the condensation
of phenol with ethyl 2-chloro-2-methylpropionate in the
presence of a dehydrochlorinating agent, followed by chlorination
and purification. It can also be synthesized by the
condensation of p-chlorophenol with acetone and chloroform
followed by esterifying the resultant acid to give clofibrate.
Chemical Properties
Clear Colorless Oil
Uses
Clofibrate is a lipid-lowering agent (antilipidemic) used for
controlling high cholesterol (anticholesteremic) and triacylglyceride
levels in the blood. It increases lipoprotein lipase
activity to promote the conversion of VLDL to LDL, thereby reducing VLDL levels. It is indicated only in subjects with
increased concentrations of VLDL and intermediate-density
lipoproteins (IDL) who have failed to respond adequately to
gemfibrozil or nicotinic acid. Clofibrate is of limited utility for
patients with either familial hypercholesterolemia or polygenic
hypercholesterolemia, as comparatively more effective drugs
are available for lowering the concentration of LDL in these
patients.
Clofibrate has no effect on hyperchylomicronemia, nor
does it affect concentrations of high-density lipoproteins
(HDL). Thus, clofibrate appears to have specific efficacy only in
patients with familial type-III hyperlipoproteinemia. There is
no substantial evidence proving efficacy of clofibrate in preventing
deaths from coronary artery disease. Clofibrate has
been used to prevent or control polydipsia, polyuria, and
dehydration in a limited number of patients with mild to
moderate neurohypophyseal diabetes insipidus. A 5-year
multicenter study reported failure of clofibrate in reducing or
preventing mortality in cardiovascular disorders, which has
provided a setback for the prophylactic use of this drug.
Definition
ChEBI: The ethyl ester of clofibric acid.
World Health Organization (WHO)
Clofibrate, an antihyperlipidaemic agent, was introduced in 1967 and was subsequently extensively studied in the primary and secondary prevention of ischaemic heart disease. Following reports, published in 1978, of increased mortality among patients receiving clofibrate in a WHO-sponsored cooperative trial concerned with the primary prevention of ischaemic heart disease, the drug was withdrawn in some countries and its approved indications were severely restricted in many others. These restrictions have become the norm for more recently developed analogues of clofibrate. (Reference: (WHODI) WHO Drug Information, 2, 6, 1979)
General Description
Clofibrate, ethyl 2-(p-chlorophenoxy)-2-methylpropionate (Atromid-S), is a stable, colorless topale yellow liquid with a faint odor and a characteristictaste. It is soluble in organic solvents but insoluble in water.
Clofibrate is prepared by a Williamson synthesis, condensingp-chlorophenol with ethyl -bromoisobutyrate, or bythe interaction of a mixture of acetone, p-chlorophenol, andchloroform in the presence of excess potassium hydroxide.The acid obtained by either of these methods is esterified togive clofibrate. Both acid and ester are active; the latter, however,is preferred for medicinal use. Clofibrate is hydrolyzedrapidly to 2-p-chlorophenoxy-2-methylpropionic acid by esterasesin vivo and, bound to serum albumin, circulates inblood. The acid has been investigated as a hypolipidemicagent. It is absorbed more slowly and to a smaller extent thanis the ester. The aluminum salt of the acid gives even lowerblood levels than p-chlorophenoxy-2-methylpropionic acid.
Hazard
Questionable carcinogen; toxic; causes nausea, vomiting, diarrhea, weakness, stiffness, cramps, and muscle tenderness.
Biological Activity
PPAR agonist (EC 50 values are 50, 500 and > 100 μ M at PPAR α , PPAR γ and PPAR δ respectively). Antihyperlipoproteinemic.
Mechanism of action
The three structurally related fibrates available in the
United States are gemfibrozil (Lopid), fenofibrate
(Tricor) and clofibrate (Atromid-S).They share common
uses and toxicities. The fibrates typically lower VLDL
triglyceride by 40% or more and elevate plasma HDL
cholesterol by 10 to 15%. The reduction of plasma
triglycerides in humans appears due to increased lipoprotein
lipase (LPL) activity. The fibrates activate a nuclear
receptor (transcription factor) termed peroxisomal proliferation
activated receptor (PPAR) that is a member of
the steroid hormone receptor superfamily. PPAR increases
transcription of the LPL gene and decreases transcription
of the apolipoprotein CIII gene (apo CIII).
Since LPL is responsible for catabolism of VLDL triglyceride
and apo CIII is an inhibitor of LPL activity, the
combined consequences of these changes are increased
LPL activity and enhanced removal of triglyceride from
the circulation.
The elevation of HDL levels by fibrates may be due
to two drug actions: induced synthesis of apo-A1, the
principal apoprotein of HDL, and increased assembly
of new HDL particles in the circulation. Surface components
of VLDL contribute to formation of HDL, as
the VLDL particles are reduced in size through the action
of LPL.The increased rate of catabolism of VLDL
caused by the fibrates would provide more components
for assembly of HDL particles.
Clinical Use
Clofibrate is the drug of choice in the treatment of typeIII hyperlipoproteinemias and may also be useful, to a lesserextent, in types IIb and IV hyperlipoproteinemias. The drugis not effective in types I and IIa.
Clofibrate can lower plasma concentrations of both triglyceridesand cholesterol, but it has a more consistent clinicaleffect on triglycerides. It also affects lipoprotein plasmalevels by enhancing removal of triglycerides from the circulationand causes reduction of VLDL by stimulatinglipoprotein lipase to increase the catabolism of this lipoproteinto LDL. Clofibrate lowers triglyceride levels in theserum much more than cholesterol levels and decreases levelsof FFAs and phospholipids. The lowering of cholesterollevels may result from more than one mechanism. Clofibrateinhibits the incorporation of acetate into the synthesis ofcholesterol, between the acetate and mevalonate step, by inhibitingsn-glyceryl-3-phosphate acyltransferase. Clofibratealso regulates cholesterol synthesis in the liver by inhibitingmicrosomal reduction of 3-hydroxy-3-methylglutaryl-CoA(HMG-CoA), catalyzed by HMG-CoA reductase. Clofibratemay lower plasma lipids by means other than impairment ofcholesterol biosynthesis, such as increasing excretionthrough the biliary tract.
Side effects
The fibrates are generally well tolerated, with GI distress being the most likely complaint. Other adverse effects include myositis and erectile dysfunction, particularly with clofibrate. There is ongoing concern about the fibrates increasing the risk of gallstones, although the extent of risk is unclear. Because clofibrate was associated with increased mortality in early clinical trials, it should be considered as a second-line drug.
Safety Profile
Poison by intravenous route.Moderately toxic by ingestion and other routes. Anexperimental teratogen. Other experimental reproductiveeffects. Reduces plasma lipid levels. Human systemiceffects by ingestion: muscle weakness, muscle spasms, andfever. Q
Drug interactions
The fibrates potentiate the actions of the coumarin anticoagulants, such as warfarin, so care should be taken to reduce the dose of simultaneously administered anticoagulants, and plasma prothrombin should be frequently measured until the level stabilizes. As mentioned earlier, great care should be given to combining a statin with a fibrate, since this combination may increase the risk of myositis and perhaps rhabdomyolysis.
Environmental Fate
Clofibrate characteristically reduces plasma triglycerides by
lowering the concentration of VLDL within 2–5 days after
initiation of therapy. In a majority of patients, total cholesterol
and LDL concentrations in plasma fall slightly. However, some
patients who exhibit a large fall in VLDL may show a paradoxical
rise in LDL, resulting in minimal net effect on total
cholesterol levels.
The drug has several proposed antilipidemic actions,
including increased triglyceride and VLDL clearance, mobilization
of cholesterol from tissues, increased fecal excretion of
neutral sterols, decreased hepatic lipoprotein synthesis and/or
secretion, decreased free fatty acid release, and decreased
triglyceride synthesis. The precise mechanisms by which clofibrate
lowers serum concentrations of triglycerides and cholesterol
are not known.
Metabolism
The pro-drug fenofibrate undergoes rapid hydrolysis to produce fenofibric acid. This active metabolite can then be further metabolized by oxidative or conjugative pathways. Gemfibrozil is slightly different in that it does not require initial bioactivation; however, similar to fenofibric acid, it can be oxidized or conjugated. Oxidation of the aromatic methyl groups produces inactive hydroxymethyl and carboxylic acid analogues. As a drug class, fibrates and their oxidized analogues are primarily excreted as glucuronide conjugates in the urine. Oxidization requires the CYP3A4 isozyme; however, because of the ability of these compounds to be conjugated and eliminated either with or without oxidation, drug interactions with other compounds affecting the CYP3A4 system are less important here than with other drug classes.
Clofibrate Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| OCEAN TRADING CORPORATION | +91(22) 24921669 | New Delhi, India | 6211 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Smruthi Organics Limited | 08069023792Ext 824 | Maharashtra, India | 17 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
| career henan chemical co | +86-0371-86658258 +8613203830695 | China | 29897 | 58 | Inquiry |
| Chongqing Chemdad Co., Ltd | +86-023-6139-8061 +86-86-13650506873 | China | 39916 | 58 | Inquiry |
| CONIER CHEM AND PHARMA LIMITED | +8618523575427 | China | 49391 | 58 | Inquiry |
| Neostar United (Changzhou) Industrial Co., Ltd. | +86-519-519-85557386 | China | 11667 | 58 | Inquiry |
Related articles
- Uses and Synthesize of Clofibrate
- Clofibrate has no effect on hyperchylomicronemia, nor does it affect concentrations of high-density lipoproteins (HDL). Thus, ....
- Jan 11，2022
637-07-0(Clofibrate)Related Search:
1of4
chevron_right